SCHEMBL24258515

SCHEMBL24258515

CN/C=C(\C=N)c1cccc(-c2ccc3c(c2)CN(C(=O)NC)CCO3)c1C(F)F

nearest known ligand 0.65

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 20/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19657623 0.79 CREBBP (1.00) CREBBP
SCHEMBL19657723 0.77 CREBBP (1.00) CREBBP
SCHEMBL19657954 0.77 CREBBP (1.00) CREBBP
SCHEMBL19657631 0.71 CREBBP (0.63) CREBBP
SCHEMBL19657427 0.70 CREBBP (1.00) CREBBP
SCHEMBL19643782 0.70 CREBBP (1.00) CREBBP
SCHEMBL30117226 0.70 CREBBP (1.00) CREBBP
SCHEMBL19657514 0.70 CREBBP (1.00) CREBBP
SCHEMBL19657518 0.70 CREBBP (1.00) CREBBP
SCHEMBL19657520 0.70 CREBBP (1.00) CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464270-B1 HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER GENENTECH INC (US) 2022-02-23 EP disclosed